infliximab 100mg powder for intravenous infusion (Remicade)

Advice

Following a full submission

infliximab (Remicade®) is accepted for restricted use within NHS Scotland for the treatment of severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapy including ciclosporin, methotrexate or psoralen ultraviolet A (PUVA).

Infliximab, compared to placebo, improves both signs and symptoms of psoriasis and quality of life in adults with plaque psoriasis. The economic case was demonstrated when used for patients with severe psoriasis who achieve a PASI 75 response or a 50% reduction in PASI and a 5 point reduction in DLQI from baseline at 10 weeks. It is one of several biologic interventions for the treatment of plaque psoriasis, some of which have lower drug acquisition costs.